Marc Yehya

Dr. Marc Yehya

Inserm U1046 Montpellier University
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in PNAS Nexus
Verified
Journal Article
Open access
PDF file
HDHaikel Dridi
Haikel Dridi
MYMarc Yehya
Marc Yehya
RBRobert Barsotti
Robert Barsotti
YLYang Liu
Yang Liu
SRSteven Reiken
Steven Reiken
SMStefan Matecki
Stefan Matecki
In critical care patients, the “”temporary inactivity of the diaphragm caused by mechanical ventilation (MV) triggers a series of events leading to diaphragmatic dysfunction and atrophy, commonly known as ventilator-induced diaphragm dysfunction (VIDD). While mitochondrial dysfunction related to oxidative stress is recognized as a crucial factor in VIDD, the exact molecular mechanism remains poorly understood. In this study, we observe that 6 h of MV triggers aberrant mitochondrial dynamics, resulting in a reduction in mitochondrial size and interaction, associated with increased expression of dynamin-related protein 1 (DRP1). This effect can be prevented by P110, a molecule that inhibits the recruitment of DRP1 to the mitochondrial membrane. Furthermore, isolated mitochondria from the diaphragms of ventilated patients exhibited increased production of reactive oxygen species (ROS). These mitochondrial changes were associated with the rapid oxidation of type 1 ryanodine receptor (RyR1) and a decrease in the stabilizing subunit calstabin 1. Subsequently, we observed that the sarcoplasmic reticulum (SR) in the ventilated diaphragms showed increased calcium leakage and reduced contractile function. Importantly, the mitochondrial fission inhibitor P110 effectively prevented all of these alterations. Taken together, the results of our study illustrate that MV leads, in the diaphragm, to both mitochondrial fragmentation and dysfunction, linked to the up-/down-regulation of 320 proteins, as assessed through global comprehensive quantitative proteomics analysis, primarily associated with mitochondrial function. These outcomes underscore the significance of developing compounds aimed at modulating the balance between mitochondrial fission and fusion as potential interventions to mitigate VIDD in human patients.

22 July 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
MYMarc Yehya
Marc Yehya
DBDoria Boulghobra
Doria Boulghobra
PGPierre-Edouard GRILLET
Pierre-Edouard GRILLET
PFPablo Rafael Fleitas-Paniagua
Pablo Rafael Fleitas-Paniagua
PBPatrice Bideaux
Patrice Bideaux
OCOlivier Cazorla
Olivier Cazorla
Muscle fatigue is a common symptom induced by exercise. A reversible loss of muscle force is observed with variable rates of recovery depending on the causes or underlying mechanisms. It can not only affect locomotion muscles, but can also affect the heart, in particular after intense prolonged exercise such as marathons and ultra-triathlons. The goal of our study was to explore the effect of four different natural extracts with recognized antioxidant properties on the contractile function of skeletal (locomotion) and cardiac muscles after a prolonged exhausting exercise. Male Wistar rats performed a bout of exhausting exercise on a treadmill for about 2.5 h and were compared to sedentary animals. Some rats received oral treatment of a natural extract (rosemary, buckwheat, Powergrape®, or rapeseed) or the placebo 24 h and 1 h before exercise. Experiments were performed 30 min after the race and after 7 days of recovery. All natural extracts had protective effects both in cardiac and skeletal muscles. The extent of protection was different depending on muscle type and the duration post-exercise (just after and after one-week recovery), including antiarrhythmic effect and anti-diastolic dysfunction for the heart, and faster recovery of contractility for the skeletal muscles. Moreover, the muscular protective effect varied between natural extracts. Our study shows that an acute antioxidant supplementation can protect against acute abnormal endogenous ROS toxicity, induced here by prolonged exhausting exercise.

1 October 2026 in Bioactive Materials
Verified
Journal Article
Open access
RZRichard Z. Zhuang
Richard Z. Zhuang
GDGeorgia Doufexi
Georgia Doufexi
MYMarc Yehya
Marc Yehya
Margaretha MorsinkMargaretha Morsink
Margaretha Morsink
XLXianghai Liao
Xianghai Liao
Gordana Vunjak-NovakovicGordana Vunjak-Novakovic
Gordana Vunjak-Novakovic
Congenital long QT syndrome (LQTS) predisposes patients to malignant ventricular tachycardias, yet existing in vitro models do not fully capture the clinical arrhythmic phenotypes that determine patient outcomes. We report the development of an engineered platform with mature, fully hiPSC-derived human cardiac tissues that reproduces genotype-specific ventricular tachycardia under physiologically relevant triggers. Using patient-derived and corrected hiPSCs, we engineered electromechanically matured cardiac tissues to model LQT8 and LQT2 syndromes. LQT8 tissues exhibited spontaneous early afterdepolarizations and sustained tachycardia, including monomorphic, polymorphic, and torsades de pointes-like waveforms. In contrast, LQT2 tissues remained stable under constant pacing but developed arrhythmias during dynamic rate acceleration, mirroring clinical trigger-dependent arrhythmogenicity. Frequency-domain analysis and activation mapping revealed re-entrant dynamics consistent with ventricular tachycardia-like activity. By unifying cellular-level electrophysiology with tissue-scale ECG-like arrhythmic activity, this platform enables physiologically inspired investigation of arrhythmogenic mechanisms in inherited arrhythmia syndromes.

1 November 2021 in Engineering Proceedings
Verified
Conference Paper
Open access
PDF file
TXTieying Xu
Tieying Xu
MYMarc Yehya
Marc Yehya
ADAbhishek Dahiya
Abhishek Dahiya
TGthierry gil
thierry gil
PBPatrice Bideaux
Patrice Bideaux
Aida  Todri-SanialAida Todri-Sanial
Aida Todri-Sanial
This paper presents a highly sensitive and novel wearable strain sensor using one-dimensional material for monitoring the respiration rate of an anesthetized rat. The dedicated sensitive sensor, based on carbon nanotubes mixed with poly(3,4-ethylenedioxythiophene) polystyrene sulfonate, was attached above the rat chest. A Wheatstone bridge electrical circuit, associated with a multifunction portable device, was connected to the strain sensor. The change of the strain sensor’s resistance value, induced by the mechanical deformability during the rat respiration, was detected and transformed into a voltage signal. The respiration information could be thus extracted and analyzed.

9 October 2026 in Science Advances
Verified
Journal Article
Closed access
LFLucile Fossier
Lucile Fossier
MYMarc Yehya
Marc Yehya
RZRichard Z. Zhuang
Richard Z. Zhuang
SSSri Karthika Shanmugam
Sri Karthika Shanmugam
RMRyan Mahling
Ryan Mahling
MBManu Ben-Johny
Manu Ben-Johny
Despite their emerging prominence, ion channelopathies have remained challenging to correct, as ion channel dysfunction linked to disease is multifaceted, involving changes in activity and/or localization. Yet, current corrective strategies typically focus on restoring only one aspect leading to incomplete efficacy. Here, focusing on the voltage-gated sodium channel, Na V 1.5, whose dysfunction is linked to life-threatening cardiac arrhythmias, we develop a genetically encoded bifunctional actuator as a proof-of-concept molecular strategy to reverse pathophysiological changes in channel function. Specifically, we engineer a high affinity nanobody targeting Na V 1.5 with two moieties: (i) a peptide that restores proper inactivation and (ii) a linkage-specific deubiquitinase that promotes surface-membrane localization. Functional validation in heterologous systems and in human and mouse cardiomyocytes demonstrated restoration of Na V 1.5 trafficking and/or gating. In all, this approach shows promise for reversing molecular deficits observed with Na V channelopathies and provides a framework to engineer multifunctional modulators targeting ion channelopathies.